John Quisel, Disc Medicine CEO

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

De­spite dri­ving re­duc­tions in a key bio­mark­er, Disc Med­i­cine’s drug for a rare blood dis­or­der flunked on ef­fi­ca­cy in a Phase 2 study. The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.